8-K: Vivani Medical Reports Significant Liver Fat Reduction and Durable Weight Effects with Exenatide Implant in Preclinical Studies

Vivani Medical, Inc. announced preclinical data demonstrating an 82% reduction in liver fat and durable body weight effects in obese mice and rats using its exenatide implant with NanoPortal technology.

Summary

• Vivani Medical, Inc. filed a Form 8-K to disclose a corporate slide presentation to the investment community.
• The presentation highlights preclinical results for an exenatide implant utilizing the company's NanoPortal technology.
• A single administration of the exenatide implant reduced liver fat by 82% in high-fat diet-induced obese mice after 12 weeks, as measured by Oil Red O (ORO) staining.
• The liver fat reduction results are numerically consistent with a similar investigation using semaglutide injections in high-fat diet-induced obese mice.
• The exenatide implant was associated with durable body weight effects in healthy Sprague-Dawley Rats.
• Weight change from baseline was measured for a single administration of the exenatide implant (NPM-119, ~320 nmol/kg/day) corrected to control (vehicle implant).
• Durable weight effects were observed through 105 days of treatment in all animals and through 112 days of treatment followed by a 28-day recovery period in a subset of 5 animals per group.

Sentiment

Score: 8

Explanation: The document presents strong positive preclinical data for the exenatide implant, showing significant liver fat reduction and durable weight effects, which are highly encouraging for a therapeutic in the metabolic disease space. The comparison to semaglutide further enhances the positive outlook.

Positives

• The exenatide implant demonstrated a significant 82% reduction in liver fat in obese mice after 12 weeks, indicating strong therapeutic potential for metabolic disorders.
• The liver fat reduction results are numerically consistent with those observed with semaglutide injections, suggesting comparable efficacy to a leading GLP-1 agonist.
• The NanoPortal technology delivered exenatide is associated with durable body weight effects in rats, indicating a sustained therapeutic benefit from a single administration.
• The preclinical data supports the potential of Vivani's implant technology for long-acting drug delivery.

Future Outlook

The company may elect to update the slides in the future to reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, but specifically disclaims any obligation to do so.

Management Comments

• Donald Dwyer, Chief Business Officer, signed the report on behalf of Vivani Medical, Inc.

Industry Context

This announcement relates to the rapidly evolving field of metabolic disease treatment, particularly obesity and non-alcoholic fatty liver disease (NAFLD). Exenatide is a GLP-1 receptor agonist, a class of drugs that includes highly successful medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Vivani's focus on an implantable, long-acting delivery system for exenatide positions it within the trend towards more convenient and sustained therapeutic options, potentially offering an alternative to frequent injections.

Comparison to Industry Standards

• The 82% liver fat reduction in obese mice with the exenatide implant is numerically consistent with results from a similar investigation using semaglutide injections, a leading GLP-1 agonist in the market. This suggests the exenatide implant's efficacy in liver fat reduction is comparable to established treatments in preclinical models.
• The durable body weight effects observed in Sprague-Dawley Rats with the exenatide implant, lasting over 100 days from a single administration, highlight the potential for a long-acting therapeutic profile, which could offer a significant advantage over daily or weekly injectable GLP-1 agonists in terms of patient adherence and convenience.

Stakeholder Impact

• Shareholders: Positive preclinical data could increase investor confidence and potentially lead to future stock price appreciation if the technology progresses through clinical trials.
• Patients: The development of a long-acting exenatide implant could offer a more convenient and effective treatment option for obesity and related metabolic conditions, potentially improving adherence and outcomes.
• Investment Community: The disclosure of preclinical data aims to inform and attract potential investors, highlighting the company's progress and therapeutic pipeline.

Key Dates

Keywords

Exenatide implant, NanoPortal technology, Liver fat reduction, Obesity, Weight loss, Preclinical data, Metabolic disorders, GLP-1 agonist, Drug delivery, Biotechnology, Pharmaceuticals